Leiden, the Netherlands — 27 June 2013 — Prosensa Holding B.V. (“Prosensa”) announced today the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of $13.00 per share, before underwriting discounts. Prosensa has also granted the underwriters a 30-day option to purchase up to an additional 900,000 ordinary shares to cover over-allotments, if any. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on June 28, 2013 under the symbol “RNA.”
Prosensa intends to use the proceeds from the offering to fund its current DMD development portfolio, its early-stage DMD discovery work and DMD-support projects, to fund other non-DMD projects and for working capital and general corporate purposes.
J.P. Morgan and Citigroup are acting as joint book-running managers for the offering. Leerink Swann is acting as lead manager, and Wedbush PacGrow Life Sciences, KBC Securities and Trout Capital are acting as co-managers.
A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on June 27, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204 or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 800-831-9146, email: firstname.lastname@example.org.
Notes to Editors
About Prosensa Holding B.V.
Prosensa is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease.
Issued for and on behalf of Prosensa Holding B.V.
To contact the Prosensa team at College Hill, email Prosensa@collegehill.com